Alopecia areata update

Journal of the American Academy of Dermatology

Volumn 42, Issue 4, 2000, Pages 549-566

  Madani, Shabnam ^a   Shapiro, Jerry ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b FRCPC   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; BETAMETHASONE DIPROPIONATE; CORTICOSTEROID; CYTOKINE; DIPHENCYPRONE; DITHRANOL; MINOXIDIL; SQUARIC ACID DIBUTYL ESTER; TRIAMCINOLONE ACETONIDE;

ALOPECIA AREATA; CELLULAR IMMUNITY; CLINICAL FEATURE; CONTACT URTICARIA; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED DISEASE; ECZEMA; EDEMA; HAIR GROWTH; HUMAN; HUMORAL IMMUNITY; HYPERPIGMENTATION; HYPOPIGMENTATION; IMMUNOTHERAPY; LYMPHADENOPATHY; MULTIFACTORIAL INHERITANCE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REVIEW; RISK FACTOR;

EID: 0033926846     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1067/mjd.2000.103909     Document Type: Review

References (170)

1. Proceedings of the First International Research Workshop on Alopecia Areata. J Invest Dermatol 1991;96(Suppl):67S-98S.
2. Proceedings of the second international research workshop on alopecia areata. J Invest Dermatol 1995;104(Suppl):2S-45S.
3. Muller SA, Winkelmann RK. Alopecia areata: an evaluation of 736 patients. Arch Dermatol 1963;88:290-97.
4. Shellow WV, Edwards JE, Koo JY. Profile of alopecia areata: a questionnaire analysis of patient and family. Int J Dermatol 1992;31:186-9.
5. Colombe BW, Price VH, Khoury EL. HLA class II antigen associations help to define two types of alopecia areata. J Am Acad Dermatol 1995;33:757-64.
6. Scerri L, Pace JL. Identical twins with identical alopecia areata. J Am Acad Dermatol 1992;27:766-7.
7. Jackow C, Puffer N, Hordinsky M, et al. Alopecia areata and cytomegalovirus infection in twins: genes versus environment? J Am Acad Dermatol 1998;38:418-25.
8. So A. Genetics, polymorphism and regulation of expression of HLA region genes. In: Lechler R, editor. HLA and disease. San Diego (CA): Academic Press; 1994. p. 1.
9. Price VH, Colombe BW. Heritable factors distinguish two types of alopecia areata. Dermatol Clin 1996;14:679-89.
10. Kuntz BM, Selzle D, Braun-Falco O, et al. HLA antigens in alopecia areata. Arch Dermatol 1977;113:1717.
11. Kianto U, Reunala T, Karvonen J. HLA-B12 in alopecia areata. Arch Dermatol 1977;113:1716.
12. Hacham-Zadeh S, Brautbar C, Cohen CA, et al. HLA and alopecia areata in Jerusalem. Tissue Antigens 1981;18:71-4.
13. Averbakh EV, Pospelov LE. HLA antigens in patients with alopecia areata. Vestn Dermatol Venereol 1986;1:24-6.
14. Frentz G, Thomsen K, Jakobsen BK, et al. HLA-DR4 in alopecia areata [letter]. J Am Acad Dermatol 1986;14:129-30.
15. Mikesell JF, Bergfeld WL, Braun WE. HLA-DR antigens in alopecia areata: preliminary report. Cleve Clin Q 1986;53:189-91.
16. Orecchia G, Belvedere MC, Martinetti M. Human leukocyte antigen region involvement in the genetic predisposition to alopecia areata. Dermatologica 1987;175:10-4.
17. Zhang L, Weetman AP, Friedman PS. HLA associations with alopecia areata. Tissue Antigens 1991;38:89-91.
18. Duvic M, Hordinsky MK, Fiedler VC. HLA-D locus associations in alopecia areata Drw52a may confer disease resistance. Arch Dermatol 1991;127:64-8.
19. Morling N, Frenz G, Fugger L, et al. DNA polymorphism of HLA class II genes in alopecia areata. Dis Markers 1991;9:35-42.
20. Welsh EA, Clark HH, Zane S, et al. Human leukocyte antigen-DQB01*03 alleles are significantly associated with alopecia areata. J Invest Dermatol 1994;103:758-63.
21. Duvic M, Welsh EA, Jackow C, et al. Analysis of HLA-D locus alleles in alopecia areata patients and families. Arch Dermatol 1995;104(Suppl):5S-6S.
22. Colombe BW, Price VH, Khoury EL, et al. Class II alleles in long-standing alopecia totalis/alopecia universalis and long-standing patchy alopecia areata differentiate these two clinical groups. J Invest Dermatol 1995;104(Suppl):4S-6S.
23. Colombe BW, Lou CD, Price VH. Genetic basis of alopecia areata: HLA in longstanding disease (oral presentation). Third International Research Workshop on Alopecia Areata. Washington, DC, Nov 5, 1998.
24. Carter DM, Jegasothy BV. Alopecia areata and Down syndrome. Arch Dermatol 1976;112:1397-9.
25. Du Vivier A, Munro DD. Alopecia areata, autoimmunity, and Down's syndrome. Br Med J 1975;1:191-2.
26. Tarlow JK, Clay FE, Cork MJ. Severity of alopecia areata is associated with a polymorphism in the interleukin-1 receptor antagonist gene. J Invest Dermatol 1994;103:387-90.
27. Friedmann PS. Alopecia areata and auto-immunity. Br J Dermatol 1981;105:153-7.
28. Bergfeld WF, Tam RC, Remzi BK. Alopecia areata and thyroid disease. Presented as a poster at the Third International Research Workshop on Alopecia Areata, Washington, DC, Nov 5, 1998.
29. Hordinsky M. Alopecia areata and atopy. Presented at the 53rd Annual Meeting of the American Academy of Dermatology, New Orleans, Feb 4-9 1995.
30. Wang SJ, Shohat T, Vadheim C, et al. Increased risk for type I (insulin-dependent) diabetes in relatives of patients with alopecia areata. Am J Med Genet 1994;51:234-9.
31. Hordinsky MK, Hallgren H, Nelson D, et al. Familial alopecia areata. Arch Dermatol 1984;120:464-8.
32. Werth VP, White WL, Sanchez MR, et al. Incidence of alopecia areata in lupus erythematosus. Arch Dermatol 1992;128:368-71.
33. Kubota A, Komiyama A, Hasegawa O. Myasthenia gravis and alopecia areata. Neurology 1997;48:774-5.
34. Brenner W, Diem E, Gschnait F. Coincidence of vitiligo, alopecia, onychodystrophy, locolised scleroderma and lichen planus. Dermatologica 1979;159:356-60.
35. Boni R, Trueb RM, Wuthrich B. Alopecia areata in a patient with candidiasis-endocrinopathy syndrome. Dermatology 1995; 191:68-71.
36. Muller HK, Rook AJ, Kubba R. Immunohistology and autoantibody studies in alopecia areata. Br J Dermatol 1980;102:609-15.
37. Gilhar A, Pillar T, Assay B, et al. Failure of passive transfer of serum from patients with alopecia areata and alopecia universalis to inhibit hair growth in transplants of human scalp skin grafted on to nude mice. Br J Dermatol 1992;126:166-71.
38. Tobin DJ, Orentreich N, Fenton DA, et al. Antibodies to hair follicles in alopecia areata. J Invest Dermatol 1994;102:721-4.
39. Tobin DJ, Hann S, Song M, et al. Hair follicle structures targeted by antibodies in patients with alopecia areata. Arch Dermatol 1997;133:57-61.
40. Friedmann PS. Decreased lymphocyte reactivity and autoimmunity in alopecia areata. Br J Dermatol 1981;105:145-52.
41. Majewski BBJ, Koh MS, Taylor DR, et al. Increased ratio of helper-to-suppressor T-cells in alopecia areata. Br J Dermatol 1984;110:171-5.
42. Hordinsky MK, Hallgren H, Nelson D. Suppressor cell number and function in alopecia areata. Arch Dermatol 1984;120:188-95.
43. Friedmann PS. Clinical and immunologic associations of alopecia areata. Semin Dermatol 1985;4:9-15.
44. Gupta AK, Ellis CN, Cooper KD, et al. Oral cyclosporine for the treatment of alopecia areata. J Am Acad Dermatol 1990;22: 242-50.
45. Olsen EA, Carson SC, Turney EA. Systemic steroids with or without 2% topical minoxidil in the treatment of alopecia areata. Arch Dermatol 1992;128:1467-73.
46. Gilhar A, Ullmann Y, Berkutzki T, et al. Autoimmune hair loss (alopecia areata) transferred by T-lymphocytes to human scalp explants on SCID mice. J Clin Invest 1998;101:62-7.
47. Paus R. Immunology of the hair follicle. In: Bos JD, editor. The skin immune system. Boca Raton (FL): CRC Press; 1997. p. 377-98.
48. Bos JD, editor.The skin immune system. Boca Raton (FL): CRC Press; 1997.
49. Paus R, Hofmann U, Eichmuller S, et al. Distribution and changing density of gamma-delta T cells in murine skin during the induced hair cycle. Br J Dermatol 1994;130:281-9.
50. Paus R, Foitzik K, Welker P, et al. Transforming growth factor-beta receptor type I and type II expression during murine hair follicle development and cycling. J Invest Dermatol 1997;109: 518-26.
51. Paus R, Van der Veen C, Eichmuller S, et al. Generation and cyclic remodeling of the hair follicle immune system in mice. J Invest Dermatol 1998;111:7-18.
52. Gillam AC, Kremer IB, Yoshida Y. The human hairfollicle:a reservoir of CD40+ B7-deficient Langerhans cells that regulate epidermis after UVB exposure. J Invest Dermatol 1998;110:422-7.
53. Westgate GE, Craggs RI, Gibson WT. Immune privilege in hair growth. J Invest Dermatol 1991;97:417-20.
54. Paus R, Eichmuller S, Hofmann U, et al. Expression of classical and nonclassical MHC class I antigens in murine hair follicles. Br J Dermatol 1994;131:177-83.
55. Paus R, Slominski A, Czarnetzki BM. Is alopecia areata an autoimmune-response against melanogenesis-related proteins, exposed by abnormal MHC class I-expression in the anagen hair bulb. Yale J Biol Med 1994;66:541-54.
56. Becker JC, Varki N, Brocker EB, et al. Lymphocyte mediated alopecia in C57BL/6 mice following successful immunotherapy for melanoma. J Invest Dermatol 1996;107:627-32.
57. Paus R. Immunology of the hair follicle. Presented at the Third International Research Workshop on Alopecia Areata. Washington, DC, Nov 5, 1998.
58. Philpott MP, Sanders DA, Bowen J, et al. Effects of interleukins, colony-stimulating factor and tumor necrosis factor on human hair follicle growth in vitro: a possible role for interleukin-1 and tumor necrosis factor-α in alopecia areata. Br J Dermatol 1996;135:942-8.
59. Mosmann TR, Coffman RL.TH1 and TH2 cells:different patterns of lymphokine secretion lead to different function properties. Annu Rev Immunol 1989;7:145-73.
60. Kapsenberg ML, Wierenga EA, Bos JD. Functional subsets of allergen-reactive human CD4+ T cells. Immunol Today 1991; 12:392-5.
61. Hoffmann R, Eicheler W, Huth A, et al. Cytokines and growth factors influence hair growth in vitro: possible implications for the pathogenesis and treatment of alopecia areata. Arch Dermatol Res 1996;288:153-6.
62. Skinner RB Jr, Light WH, Bale GF. Alopecia areata and the presence of cytomegalovirus DNA. JAMA 1995;273:1419-20.
63. Tosti A, Gentilomi G, Venturoli S. No correlation between cytomegalovirus and alopecia areata. J Invest Dermatol 1996; 107:443.
64. Garcia-Hernandez MJ, Torres MJ, Palomares JC, et al. No evidence of cytomegalovirus DNA in alopecia areata [letter]. J Invest Dermatol 1998;110:185.
65. McElwee KJ, Boggess D, Burgett B, et al. Murine cytomegalovirus is not associated with alopecia areata in C3H/HeJ mice [letter]. J Invest Dermatol 1998;110:986-7.
66. Baker GHB. Psychological factors and immunity. J Psychosom Res 1987;31:1-10.
67. Perini GI. Life events and alopecia areata. Psychother Psychosom 1984;41:48-52.
68. Colon EA. Lifetime prevalence of psychiatric disorders in patients with alopecia areata. Compr Psychiatry 1991;32:245-51.
69. De Waard-Van der Spek FB, Oranje AP, De Raeymaecker DM, et al. Juvenile versus maturity-onset alopecia areata: a comparative retrospective clinical study. Clin Exp Dermatol 1989;14: 429-36.
70. Van der Steen P, Boezeman J, Duller P, et al. Can alopecia area-ta be triggered by emotional stress? Acta Derm Venereol (Stockh) 1992;72:279-80.
71. Tobin SJ. Morphological analysis of hair follicles in alopecia areata. Microsc Res Tech 1997;38:443-51.
72. Tobin DJ, Fenton DA , Kendall MD. Ultrastructural observations on the hair bulb melanocytes and melanosomes in acute alopecia areata. J Invest Dermatol 1990;94:803-7.
73. Nutbrown M, MacDonald-Hull SP, Cunliffe WJ, et al. Abnormalities in the ultrastructure of melanocytes and the outer root sheath of clinically normal hair follicles from alopecia areata scalps. J Invest Dermatol 1995;104(Suppl):12S-13S.
74. Hsoi J, Murphy GF, Egan CL, et al. Regulation of Langerhans cell function by nerves containing calcitonin gene-related peptide. Nature 1993;363:159-63.
75. Hordinsky M, Lorimer S, Worel S. Innervation and vasculature of the normal human and alopecia areata hair follicle: an immunohistochemical and laser scanning confocal microscope study. In: Proceedings of the First Tricontinental Meeting of Hair Research Societies, Brussels, Belgium, 1995.
76. Hordinsky M, Kennedy W, Wendelschafer-Crabb G, et al. Structure and function of cutaneous nerves in alopecia areata. J Invest Dermatol 1995;104(Suppl):28S-29S.
77. Raud J, Lundeberg T, Brodda-Jansen G, et al. Potent antiinflammatory action of calcitonin gene-related peptide. Biochem Biophys Res Commun 1991;180:1429-35.
78. Paus R, Heinzelmann T, Schultz K-D, et al. Hair growth induction by substance P. Lab Invest 1994;71:134-40.
79. Ericson M, Binstock K, Guanche A, et al. Differential expression of substance P in perifollicular scalp blood vessels and nerves after topical therapy with capsaicin 0.075% (Zostrix HP) in controls and patients with extensive alopecia areata. J Invest Dermatol 1999;112:653.
80. Sundberg JP, Cordy WR, King LE. Alopecia areata in aging C3H/HeJ mice. J Invest Dermatol 1994;102:847-56.
81. Michie HJ, Jahoda CAB, Oliver RF, et al. The DEBR rat: an animal model of human alopecia areata. Br J Dermatol 1991;125:94-100.
82. Smyth JR. Alopecia areata and universalis in the Smyth chicken model for spontaneous autoimmune vitiligo. Presented at the Third International Research Workshop on Alopecia Areata. Washington, DC, Nov 5, 1998.
83. McElwee KJ, Boggess D, King Jr LE, et al. Experimental induction of alopecia areata-like hair loss in C3H/HeJ mice using full-thickness skin grafts. J Invest Dermatol 1998;111:797-803.
84. Messenger AG, Slatter DN, Bleehen SS. Alopecia areata: alterations in the hair growth cycle and correlation with the follicular pathology. Br J Dermatol 1986;114:337-47.
85. Peereboom-Wynia JDR, Koerten HK, Van Joost TH, et al. Scanning electron microscopy comparing exclamation mark hairs in alopecia areata with normal hair fibers, mechanically broken by traction. Clin Exp Dermatol 1989;14:47-50.
86. Headington JT. The histopathology of alopecia areata [abstract]. J Invest Dermatol 1991;96(Suppl):69S.
87. Perret C, Wiesner-Menzel L, Happle R. Immunohistochemical analysis of T-cell subsets in the peribulbar and intrabulbar infiltrates of alopecia areata. Acta Derm Venereol (Stockh) 1984;64:26-30.
88. Wiesner-Menzel L, Happle R. Intrabulbar and peribulbar accumulation of dendritic OKT 6-positive cells in alopecia areata. Arch Dermatol Res 1984;276:333-4.
89. Whiting DA, Howsden FL, editors. Alopecia areata: Color atlas of differential diagnosis of hair loss. Cedar Grove (NJ):Canfield Publishing; 1996. p. 32-7.
90. Whiting DA. Histopathology of alopecia areata in horizontal sections of scalp biopsies. J Invest Dermatol 1995;104(Suppl): 26S-7S.
91. Kohchiyama A, Hatamochi A, Ueki H. Increased number of OKT6-positive dendritic cells in the hair follicles of patients with alopecia areata. Dermatologica 1985;171:327-31.
92. Elston DM, McCollough MLM, Bergfeld WF, et al. Eosinophils in fibrous tracts and near hair bulbs: a helpful diagnostic feature of alopecia areata. J Am Acad Dermatol 1997;37:101-6.
93. Nutbrown M, Hull SPM, Baker TG, et al. Ultrastructural abnormalities in the dermal papillae of both lesional and clinically normal follicles from alopecia areata scalps. Br J Dermatol 1996;135:204-10.
94. McDonagh AJG, Snowden JA, Stierle C. HLA and ICAM-1 expression in alopecia areata in vivo and in vitro: the role of cytokines. Br J Dermatol 1993;129:250-6.
95. Lee JY, Hsu ML. Alopecia syphilitica, a simulator of alopecia areata: histopathology and differential diagnosis. J Cutan Pathol 1991;18:87-92.
96. Dawber RPR, de Berker D, Wojnarowska F. Disorders of hair. In: Champion RH, Burton JL, Burns DA, editors. Rook/Wilkinson/ Ebling Textbook of dermatology. Boston: Blackwell Science; 1998. p. 2869-973.
97. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey [letter]. Arch Dermatol 1992;128:702.
98. Safavi KHH, Muller SA, Suman VJ, et al. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc 1995;70:628-33.
99. Price V. Alopecia areata: clinical aspects. J Invest Dermatol 1991;96(Suppl):68S.
100. Camacho F. Alopecia areata: clinical features. Dermatopathology. In: Camacho F, Montagna W, editors. Trichology: diseases of the pilosebaceus follicle. Madrid: Aula Medica Group; 1997. p. 417-40.
101. Muralidhar S, Sharma VK, Kaur S. Ophiasis inversus:a rare pattern of alopecia areata [letter]. Pediatr Dermatol 1998;15:326-7.
102. Orecchia G, Douville H, Marelli MA. Nail changes and alopecia areata. Ital Gen Rev Dermatol 1988;25:179-84.
103. Berker DAR, Baran R, Dawber RPR, editors. Handbook of diseases of the nails and their management. Oxford: Blackwell Science Ltd; 1995. p. 76-7.
104. Mitchell A, Krull E. Alopecia areata: pathogenesis and treatment. J Am Acad Dermatol 1984;11:763-75.
105. Madani S, Shapiro J. The scalp biopsy: making it more efficient. Dermatol Surg 1999;25:537-8.
106. Olsen E, Hordinsky M, McDonald-Hull S, et al. Alopecia areata investigational assessment guidelines. J Am Acad Dermatol 1999;40:242-6.
107. Shapiro J. Alopecia areata: update on therapy. Dermatol Clin 1993;11:35-46.
108. Sawaya ME, Hordinsky MK. Glucocorticoid regulation of hair growth in alopecia areata.J Invest Dermatol 1995;194(Suppl 5):30S.
109. Montes L. Topical halcinonide in alopecia areata and alopecia totalis. J Cutan Pathol 1977;4:47-50.
110. Gill K, Baxter D. Alopecia totalis: treatment with fluocinolone acetonide. Arch Dermatol 1963;87:384.
111. Shapiro J, Price V. Hair regrowth: therapeutic agents. Dermatol Clin 1998;16:341-56.
112. Price V, Khoury E. Progress in dermatology. Bull Dermatol Found 1991;25:1.
113. Buhl AE. Minoxidil's action in hair follicles. J Invest Dermatol 1991;96(Suppl):73S-4S.
114. Khoury EL, Price VH, Abdel-Salam MM, et al.Topical minoxidil in alopecia areata: no effect on the perifollicular lymphoid infiltration. J Invest Dermatol 1992;99:40-7.
115. Fiedler-Weiss V, Rumsfield J, Buys C. Evaluation of oral minoxidil in the treatment of alopecia areata. Arch Dermatol 1987; 123:1488-90.
116. Price VH. Double-blind, placebo-controlled evaluation of topical minoxidil in extensive alopecia areata. J Am Acad Dermatol 1987;16:730-6.
117. Shapiro J, Price V. Hair regrowth: therapeutic agents. Dermatol Ther1998;16:341-56.
118. Price V. Topical minoxidil (3%) in extensive alopecia areata including long-term efficacy. J Am Acad Dermatol 1987;16: 737.
119. Fiedler V, Vendrow A, Szunpar G. Treatment-resistant alopecia areata: response to combination therapy with minoxidil plus anthralin. Arch Dermatol 1990;126:756-9.
120. Fiedler V. Alopecia areata: current therapy. J Invest Dermatol 1991;96(Suppl):69S.
121. Fiedler-Weiss V. Topical minoxidil solution (1% and 5%) in the treatment of alopecia areata. J Am Acad Dermatol 1987;16: 737-44.
122. Fiedler VC. Alopecia areata. Arch Dermatol 1992;128:1519-29.
123. Fiedler-Weiss V, Buys C. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol 1987;123:1491-3.
124. Fiedler VC, Alaiti S. Treatment of alopecia areata. Dermatol Clin 1996;14:733-8.
125. Shapiro J. Topical immunotherapy in the treatment of chronic severe alopecia areata. Dermatol Clin 1993;11:611-7.
126. Pericin M, Trueb RM. Topical immunotherapy of severe alope-cia areata with diphenylcyclopropenone: evaluation of 68 cases. Dermatology 1998;196:418-21.
127. Rokhsar CK, Shupack JL, Vafai JJ, et al. Efficacy of topical sensitizers in the treatment of alopecia areata. J Am Acad Dermatol 1998;39:751-61.
128. Happle R, Klein H, Macher E. Topical immunotherapy changes in the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res 1986;278:214-8.
129. Shapiro J, Sundberg JP, McElwee KJ, et al. Immunophenotypic profiles during topical immunotherapy of alopecia areata in mice and rats with diphencyprone. Presented at the Third International Research Workshop on Alopecia Areata. Washington, DC, Nov 5, 1998.
130. Freyschmidt-Paul P, Sundberg JP, Boggess D, et al. Successful topical immunotherapy of alopecia areata-like hair loss in C3H/HEJ mice. Presented at the Third International Research Workshop on Alopecia Areata. Washington, DC, Nov 5, 1998.
131. Daman L, Rosenberg W, Drake L. Treatment of alopecia areata with dinitrochlorobenzene. Arch Dermatol 1978;114:1036-8.
132. Happle R. Antigenic competition as a therapeutic concept for alopecia areata. Arch Dermatol Res 1980;267:109-14.
133. Goldsmith L. Summary of alopecia areata research workshop and future research directions. J Invest Dermatol 1991;96 (Suppl):98S-100S.
134. Kratka J, Goerz G, Vizethum W. Dinitrochlorobenzene: influence on the cytochrome P450 system and mutagenic effects. Arch Dermatol Res 1979;266:315.
135. Summer K, Goggelmann W. 1-Chloro-2,4-dinitrochlorobenzene depletes glutathione in rat skin and is mutagenic. Mutat Res 1980;77:91-3.
136. Tosti A, De Padova MP, Minghetti G, et al. Therapies versus placebo in the treatment of patchy alopecia areata. J Am Acad Dermatol 1986;15:209-10.
137. Tosti A, Guidetti MS, Bardazzi F, et al. Long-term results of topical immunotherapy in children with alopecia totalis or alopecia universalis. J Am Acad Dermatol 1996;35:199-201.
138. Micali G, Licastro-Cicero R, Nasca MR. Treatment of alopecia areata with squaric acid dibutylester. Int J Dermatol 1996;35: 52-6.
139. Happle R, Kalveran K, Buchner U, et al. Contact allergy as therapeutic tool for alopecia areata: application of squaric acid dibutylester. Dermatologica 1980;161:289-97.
140. Flowers F, Slazinski L, Fenske N, et al. Topical squaric acid dibutylester therapy for alopecia areata. Cutis 1982;30:733-6.
141. Gianetti A, Orecchia G. Clinical experience on the treatment of alopecia areata with squaric acid dibutylester. Dermatologica 1983; 167:280-2.
142. Strobel R, Rohrborn G. Mutagenic and cell transformation activities of 1-chloro-2,4-dinitrobenzene and squaric acid dibutylester. Arch Toxicol 1980;435:307-14.
143. Wilkerson MG, Henkin J, Wilkin JK. Diphenylcyclopropenone: examination for potential contaminants, mechanisms of sensitization, and photochemical stability. J Am Acad Dermatol 1984;11:802-7.
144. Wilkerson MG, Henkin J, Wilkin JK, et al. Squaric acid and esters: analysis for contaminants and stability in solvents. J Am Acad Dermatol 1985;13:229-34.
145. Orecchia G, Rabbiosi G. Treatment of alopecia areata with diphencyprone. Dermatologica 1990;171:193-6.
146. Monk B. Induction of hair growth in alopecia totalis with diphencyprone sensitization. Clin Exp Dermatol 1989;14:154-7.
147. Shapiro J, Tan J, Ho V, et al. Treatment of chronic severe alopecia areata with topical diphenylcyclopropenone and 5% minoxidil: a clinical and immunopathologic evaluation. J Am Acad Dermatol 1993;29:729-35.
148. MacDonald-Hull S, Cunliffe W. Successful treatment of alopecia areata using the contact allergen diphencyprone [letter]. Br J Dermatol 1991;123:212.
149. Van der Steen P, Van Baar H, Perret C. Treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991;24:227-30.
150. Van der Steen P, Boezeman J, Happle R. Topical immunotherapy for alopecia areata: re-evaluation of 139 cases after additional follow-up perid of 19 months. Dermatology 1992;184: 198-201.
151. Gordon P, Aldridge G, McVittie E, et al. Topical diphencyprone for alopecia areata: evaluation of 48 cases after 30 months' follow-up. Br J Dermatol 1996;134:869-71.
152. Happle R, Hausen B, Wiesner-Menzel L. Diphencyprone in the treatment of alopecia areata. Acta Derm Venereol (Stockh) 1983;63:49-52.
153. Van der Steen PHM, Van Baar HMJ, Happle R, et al. Prognostic factors in the treatment of alopecia areata with diphenylcyclopropenone. J Am Acad Dermatol 1991;24:227-30.
154. Weise K, Kretzschmar L, John SM, et al.Topical immunotherapy in alopecia areata: anamnestic and clinical criteria of prognostic significance. Dermatology 1996;192:129-33.
155. Wilkerson M, Connor TH, Henkin J, et al. Assessment of diphenylcyclopropenone for photochemically induced mutagenicity in the Ames assay. J Am Acad Dermatol 1987;17:606-11.
156. Shapiro J, Madani S. Alopecia areata: diagnosis and management. Int J Dermatol 1999;38(Suppl 1):19-24.
157. Tosti A, Guerra L, Bardazzi F. Contact urticaria during topical immunotherapy. Contact Dermatitis 1989;21:196-7.
158. Hatzis J, Gourgiotou K, Tosca A. Vitiligo as a reaction to topical treatment with diphencyprone. Dermatologica 1988;177:146-8.
159. Perret C, Steijlen P, Zaun H, et al. Erythema multiforme-like eruptions: a rare side effect of topical immunotherapy with diphenylcyclopropenone. Dermatologica 1990;180:5-7.
160. Ree K. Reduction of Langerhans cells in human epidermis during PUVA therapy: a morphometric study. J Invest Dermatol 1982;78:488.
161. Mitchell A, Douglas M. Topical photochemotherapy for alopecia areata. J Am Acad Dermatol 1985;12:644-9.
162. Larko O, Swanbeck G. PUVA treatment of alopecia areata. Acta Derm Venereol (Stockh) 1983;63:546.
163. Lassus A, Kianto U, Johansson E. PUVA treatment for alopecia areata. Dermatologica 1980;161:298-304.
164. Claudy A, Gagnaire D. Photochemotherapy for alopecia areata. Acta Derm Venereol (Stockh) 1980;60:171-2.
165. Stern R, Nichols K, Vakeva L. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet light A radiation (PUVA). N Engl J Med 1997;336:1041-5.
166. Whiting D. The treatment of alopecia areata. Cutis 1987; 40:247-50.
167. Friedli A, Labarthe MP, Engelhardt E, et al. Pulse methylprednisolone therapy for severe alopecia areata: an open prospective study of 45 patients. J Am Acad Dermatol 1998;39:597-602.
168. Gupta A, Ellis C, Cooper K, et al. Oral cyclosporine for the treatment of alopecia areata: a clinical and immunohistochemical analysis. J Am Acad Dermatol 1990;22:242-50.
169. Shapiro J, Lui H, Tron V, Ho V, et al. Systemic cyclosporine and low-dose prednisone in the treatment of chronic severe alopecia areata: a clinical and immunopathologic evaluation. J Am Acad Dermatol 1997;36:114-7.
170. Van der Velden EM, Drost BH, Ijsselmuiden OE, et al. Dermatography as a new treatment for alopecia areata of the eyebrows. Int J Dermatol 1998;37:617-21.